Literature DB >> 7626823

Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors.

L Chang1, D McBride, B L Miller, M Cornford, R A Booth, S D Buchthal, T M Ernst, D Jenden.   

Abstract

Results of magnetic resonance spectroscopic (MRS) studies of the chemical patterns in brain tumors have been inconsistent. Actual biochemical correlations are needed. In 2 patients with heterogeneous intracranial tumors, in vivo 1H MRS and in vitro biochemical analyses were correlated. Histology confirmed the tumor heterogeneity. Choline was elevated in the cellular portion of both tumors but decreased in the necrotic or cystic portions. Creatine was diffusely decreased while lactate was elevated in all regions of both tumors. Furthermore, the increase in the choline peak on 1H MRS appeared to be due to increases in water-soluble choline compounds. This study illustrates the value of small localized voxels for differentiating regional chemical differences in tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7626823     DOI: 10.1111/jon199553157

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  23 in total

1.  Total choline at 1H-MRS and [18F]-fluoromethylcholine uptake at PET.

Authors:  Sandi Kwee; Thomas Ernst
Journal:  Mol Imaging Biol       Date:  2010-08       Impact factor: 3.488

2.  Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy.

Authors:  Casilda Balmaceda; Dana Critchell; Xiangling Mao; Kenneth Cheung; Susan Pannullo; Robert L DeLaPaz; Dikoma C Shungu
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo.

Authors:  Xiaojuan Li; Daniel B Vigneron; Soonmee Cha; Edward E Graves; Forrest Crawford; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

Review 4.  Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer.

Authors:  Kristine Glunde; Dmitri Artemov; Marie-France Penet; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 5.  Interrogating Metabolism in Brain Cancer.

Authors:  Travis C Salzillo; Jingzhe Hu; Linda Nguyen; Nicholas Whiting; Jaehyuk Lee; Joseph Weygand; Prasanta Dutta; Shivanand Pudakalakatti; Niki Zacharias Millward; Seth T Gammon; Frederick F Lang; Amy B Heimberger; Pratip K Bhattacharya
Journal:  Magn Reson Imaging Clin N Am       Date:  2016-11       Impact factor: 2.266

6.  Variation of post-treatment H-MRSI choline intensity in pediatric gliomas.

Authors:  J A Lazareff; R K Gupta; J Alger
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

7.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.

Authors:  Janine M Lupo; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

8.  The correlation between 1H MRS choline concentrations and MR diffusion trace values in human brain tumors.

Authors:  Dita Wagnerova; Filip Jiru; Monika Dezortova; Lydie Vargova; Eva Sykova; Milan Hajek
Journal:  MAGMA       Date:  2008-10-25       Impact factor: 2.310

9.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.

Authors:  Suja Saraswathy; Forrest W Crawford; Kathleen R Lamborn; Andrea Pirzkall; Susan Chang; Soonmee Cha; Sarah J Nelson
Journal:  J Neurooncol       Date:  2008-09-23       Impact factor: 4.130

10.  Preoperative proton-MR spectroscopy of gliomas--correlation with quantitative nuclear morphology in surgical specimen.

Authors:  Reinhold Nafe; Sebastian Herminghaus; Peter Raab; Sabine Wagner; Ulrich Pilatus; Berthold Schneider; Wolfgang Schlote; Friedhelm Zanella; Heinrich Lanfermann
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.